The 5 most entry-ready markets for medical devices right now

Not all markets are equally hard to enter. For a Class II device, the fastest routes right now belong to the markets that let you build on an approval you already hold somewhere else. That single feature, regulatory reliance, is reshaping where and in what order companies launch.

The five below are ranked on the first two dimensions of the Vantro market entry framework, regulatory pathway and timeline to commercial launch, with local partner requirements noted for each because they determine when the clock actually starts. Reliance weighs most, because it is the difference between months of duplicated review and a pathway that recognises work already done.

Every figure below is a published regulator number, cited. Where a regulator does not publish something, this piece says so rather than estimating.

1. Singapore

Singapore is the clearest case of reliance done well, and in March 2026 it became the first regulator in the world to reach WHO Maturity Level 4 for medical device regulatory systems¹.

The Health Sciences Authority names five reference regulatory agencies: Australia TGA, EU Notified Bodies, Health Canada, Japan Ministry of Health, Labour and Welfare, and the US FDA².

The distinction that matters, and that most coverage misses, is between those five and the four independent reference agencies. HSA collapses TGA and EU Notified Bodies into a single grouping. So a manufacturer holding a TGA approval and an EU CE mark holds one independent approval, not two. That matters because the faster routes require two.

One reference approval qualifies a device for the abridged route: 100 working days for Class B, 160 for Class C, 220 for Class D, against 160, 220 and 310 on the full route³. Useful, but a saving of roughly a third, not a transformation.

The transformation is further up. Two independent approvals, or one plus three years of clean marketing history, qualify a Class B device for the immediate route, which is granted on submission. Class C drops to 120 working days on the expedited route, Class D to 180. Class D has no immediate route.

What a Singapore registration does not do. It is not a regulatory gateway to ASEAN. An HSA registration confers no market access elsewhere in the bloc. The ASEAN Medical Device Directive harmonises technical requirements and the submission dossier but creates no mutual recognition: a medical device to be placed on the market of a Member State shall be registered with the Regulatory Authority of that Member State⁴. Singapore is a strong first ASEAN market and a commercial hub. Budget for five registrations, not one.

2. Malaysia

Malaysia is usually described as a Singapore satellite. That undersells it.

Malaysia runs its own abridged route, Conformity Assessment by Way of Verification, recognising seven authorities: EU Notified Bodies, Japan MHLW, Australia TGA, Health Canada, US FDA, the UK MHRA, and Singapore HSA⁵. The UK inclusion is the one most competing coverage misses.

The condition that catches people is time on market. The device must have been marketed for a minimum of one year in the approving jurisdiction, with the same design and intended purpose, no deaths or serious deterioration in health, no open recalls, and no prior rejection or withdrawal⁵. A recent clearance does not qualify.

Malaysia other advantage is the Medical Device Regulatory Reliance Programme with Singapore, which ran as a pilot from 1 September 2025 and moved to full implementation on 1 March 2026 with no stated end date⁶⁷. It runs in both directions and covers Class B, C and D. Class A is excluded, as are devices the two authorities classify differently and Class D devices containing a registrable drug in an ancillary role.

The published benefit: a Singapore approval into Malaysia takes 30 working days of verification plus 30 working days of MDA registration, against 60 working days on standard assessment. A Malaysian approval into Singapore gets up to 30 percent shorter review across Class B to D⁶. The benefit is time. There is no fee reduction.

What it is not. It is not passporting. The device still needs full in country registration, an establishment licence under section 15(1) of the Medical Device Act 2012, and an Authorised Representative that is licensed and domiciled in Malaysia. MDA is explicit that an AR cannot be the brand owner⁸. A Singapore entity cannot serve as your Malaysian AR. Sequence the two markets together, but staff them separately.

3. Australia

Australia system is mature, closely aligned with the EU framework, and built to accept work done elsewhere. The mechanism is the use of market authorisation evidence from comparable overseas regulators and assessment bodies, and the terminology matters more than it sounds.

For most overseas manufacturers, a CE certificate or other comparable overseas regulator evidence is submitted as manufacturer evidence accompanying an application for inclusion in the ARTG. The TGA does not re run a conformity assessment. Abridged assessment is a real statutory term, but it applies to applications for a TGA Conformity Assessment certificate, which is a different and narrower route⁹.

MDSAP sits alongside this rather than inside it. MDSAP is a quality management system audit programme, not a market authorisation. An MDSAP certificate substitutes for TGA on site auditing of the manufacturer; a CE certificate is market authorisation evidence. They do different jobs and are not interchangeable¹⁰.

On timelines. The TGA does not currently publish device processing figures; its most recent benchmarking data dates from 2019. What is fixed in law is the ceiling: a conformity assessment application requiring design examination runs on a 255 working day statutory clock, with the clock stopped for information requests¹¹. The variable that moves everything else is whether an application is selected for audit.

An Australian sponsor is mandatory. The sponsor must be a recognised Australian based legal entity, holds the ARTG entry, and carries the section 41FD certifications, the automatic conditions, adverse event reporting and recall duties¹². It is a legal prerequisite and an ongoing accountable role, not an administrative formality.

Watch this. A TGA consultation on conformity assessment procedures closed on 14 April 2026 and has produced no legislation as at August 2026. The proposals include formally recognising MDSAP as QMS evidence and reclassifying reusable surgical instruments from Class I to Class IIa. The consultation paper states that none of its proposals would change how the TGA recognises comparable overseas regulator approvals¹³.

4. UAE

The UAE is the most credible single entry point into MENA, and as of 2025 it is also the most clearly priced.

Legal competence for medical device marketing authorisation now sits with the Emirates Drug Establishment, under Federal Decree-Law 28/2023 and Federal Decree-Law 38/2024, the latter effective 2 January 2025¹⁴¹⁵. EDE remit expressly includes the free zones, so a free zone entity does not escape registration.

The published numbers, from EDE and from Cabinet Resolution 40/2025¹⁶¹⁷: new device marketing authorisation, 45 working days, AED 100 application plus AED 5,000 issuance. Renewal, 15 working days, AED 100 plus AED 2,500. Registration validity, five years. Product classification, AED 500.

Sequence matters here more than anywhere else on this list. The establishment is licensed first, the product second. EDE states that marketing authorisation holders must be registered by Emirates Drug Establishment before they could register their products, and the applicant must be an EDE licensed medical warehouse or marketing office¹⁶. A foreign manufacturer cannot hold a UAE device registration directly.

On reliance, be precise. The UAE has no named verification, abridged or reliance route for devices. There is a single marketing authorisation application, within which prior foreign approval functions as supporting evidence. EDE asks for a certificate of quality conformity or marketing authorisation such as EC, 510(K), PMA, plus a certificate of free sale from the country of origin legalised by the UAE Embassy¹⁶. Federal Decree-Law 38/2024 refers to reference countries, but no device specific reference authority list is published on the EDE portal.

One correction worth making because it appears widely: the European Medicines Agency does not regulate medical devices. EU devices are CE marked by notified bodies designated by member states¹⁸. If a source lists EMA as a device reference authority, treat the rest of that source with care.

On ownership. Free zones allow 100 percent foreign ownership, but so does the mainland. Since the 2020 Commercial Companies Law amendments, full foreign ownership is available for mainland companies across most activities, subject to emirate level approved activity lists, 1,105 activities in Abu Dhabi and over 1,000 in Dubai, with a carve out for activities of strategic impact¹⁹. Choose a free zone for customs, tax or clustering reasons, not because it is the only route to ownership.

5. India

India is on this list for scale rather than speed, and the distinction is worth stating plainly.

India has no reliance route. It is the only market of the five where a prior approval elsewhere does not shorten the pathway.

For a foreign entrant, the relevant pathway is import, and it is centrally licensed regardless of risk class. An application in Form MD-14 to the Central Licensing Authority leads to a licence in Form MD-15 within a period of nine months from the date of application under Rule 36(1) of the Medical Devices Rules 2017²⁰. Domestic manufacture of a Class B device is different: it is licensed by the State Licensing Authority in Form MD-5, on a sequential timetable of 90 plus 30 plus 20 days under Rule 20(6), so roughly 140 days.

Two practical corrections that circulate widely. Medical device applications are filed through the CDSCO Online System for Medical Devices, not the SUGAM portal, which handles drugs, cosmetics and clinical trials²¹. And Class B licensing authority depends on manufacture versus import, which most summaries collapse.

Why it still ranks. The market is large and structurally import dependent. In FY 2024-25, India exported Rs 42,360 crore of medical devices against imports of Rs 137,088 crore, a ratio of roughly 3.2 to 1²². The Government of India values the industry at over USD 15 billion and describes it as one of the fastest growing segments of its healthcare sector²³. Note the wording: that is a domestic comparison, not a global ranking, and official 2030 projections vary between USD 30 billion and USD 50 billion across government releases.

Watch this. A draft amendment, G.S.R. 515(E) of 23 June 2026, proposes shortening several licensing timelines, including Rule 25(1) from 45 days to 20²⁴. It is not in force. If it is finalised, India position on this list changes.

The pattern worth noticing

Every market above India rewards the same thing: an approval you already hold somewhere else. The question is no longer only whether you can get approved here. It is which approval unlocks the most markets next.

Three things follow from the sources above that are easy to miss.

Independence beats quantity. Singapore four independent groupings, not five agencies, is what determines route eligibility. Two approvals that collapse into one grouping buy you nothing.

Time on market is a gate. Malaysia requires a year. Singapore immediate and expedited routes reward three. A first approval has an ageing value that a regulatory timeline chart will not show you.

Local presence sets the start line. Singapore needs a registrant, Malaysia an AR domiciled in country, Australia a sponsor, the UAE an EDE licensed establishment registered before any product application, India an authorised agent. The regulatory clock does not start until this exists. In the UAE it is formally sequential.

This is the general picture for a Class II device. Your class, your product and your target list change the ranking. A Class III implantable faces a different landscape, and procurement structure, pricing environment and tax and customs exposure, the other three dimensions of the framework, can move a market regardless of regulatory speed.

Methodology

Markets are assessed against a published six dimension framework: regulatory pathway, timeline to commercial launch, procurement structure, pricing environment, local partner requirements, and tax and customs exposure. This ranking uses the first two, with the fifth noted per market. The framework is set out in A Structured Framework for Systematic Life Sciences Market Entry Assessment, SSRN, posted 15 June 2026, validated across 90 markets including all 50 US states.

Every claim here is sourced to a national regulatory authority, a government legislative register, or a multilateral body. Where a regulator does not publish a figure, none is given.

Ranking as at 12 August 2026. Regulatory positions change; verify before acting.